HengHong Technology is a pharmaceutical distributor based in Hainan Province, China. The company distributes traditional Chinese medicines (TCMD) and chemical medicines to pharmacies, hospitals, clinics, and other distributors across 22 provinces in China. HengHong's core product line is TCMD cold, flu, and cough remedies — established OTC products with strong consumer recognition in China. The company also sells tonic TCMD for general wellness and a smaller line of chemical medicines. HengHong sells through a tiered distribution network, selecting two to three leading local distributors per market who then resell to retailers and pharmacies, and also sells directly to large chain pharmacy groups and through online channels. The business model is straightforward: buy products from suppliers and resell at a markup, with gross margins around 22-23%. HengHong runs a "light asset" model with no manufacturing and minimal capex, making working capital management a key operational focus. A notable structural feature is heavy related-party dependency — one supplier, Guangdong Hengcheng Pharmaceutical, controlled by the Chairman's family, accounted for roughly 97% of product purchases in FY2024, making HengHong effectively a distribution arm for that manufacturer. Demand is mildly seasonal, peaking in winter. HengHong's growth strategy focuses on acquiring distribution rights for new TCMD products, expanding into international markets, and building a digital marketing platform. Chairman Weixiong Tan controls 74.6% of shares post-IPO.